Natco Pharma Limited Share Price & Analysis

Natco Pharma announces board meeting outcomes.

*Natco Pharma announces board meeting outcomes.* The company disclosed outcomes from its September 09, 2026, board meeting via a corporate filing. No major decisions or financial announcements were revealed. Routine update likely pertaining to internal approvals or compliance. 📊 *STOCKS:* $NATCOPHARM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma

Natco Pharma declares interim dividend for FY26-27

*Natco Pharma declares interim dividend for FY26-27.* The board approved a dividend payout, though the exact amount remains undisclosed. This follows the company’s routine dividend schedule. Interim dividends typically support investor sentiment but don’t alter fundamentals. 📊 *STOCKS:* $NATCOPHARM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Dividend

Natco Pharma announces board meeting outcomes

*Natco Pharma announces board meeting outcomes*. The company disclosed the outcomes of its recent board meeting held on July 08, 2026. No major strategic decisions or financial announcements were revealed. The update is primarily procedural in nature with no immediate business impact. 📊 *STOCKS:* NATCOPHARM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma

Natco Pharma launches generic Carboplatin Injection in US

*Natco Pharma launches generic Carboplatin Injection in US* — Natco Pharma has announced the launch of Carboplatin Injection, a generic version of Paraplatin®, in the U.S. market. This launch expands its presence in the competitive oncology generics segment. The product is approved by the USFDA and will be marketed by partner Sagent Pharmaceuticals. **First-to-file** status may offer **180-day marketing exclusivity**, boosting near-term revenue potential. 📊 *STOCKS:* $NATCOPHARM | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #DrugLaunch

Natco Pharma announces 2:21 rights issue at ₹750 per share

*Natco Pharma announces 2:21 rights issue at ₹750 per share*. The rights issue allows shareholders to subscribe to **2 new shares for every 21 held** at an issue price of **₹750 per share**, including a premium of **₹748**. The move aims to strengthen the company's capital structure and fund future growth initiatives. The rights will be issued in the proportion of 2:21 based on existing shareholding. 📊 *STOCKS:* $NATCOPHARM | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #RightsIssue

Natco Pharma invests in US biotech eGenesis Inc

*Natco Pharma invests in US biotech eGenesis Inc.* The company announced a strategic investment in eGenesis, Inc., a Massachusetts-based biotech firm, to explore cutting-edge biopharma opportunities. This move aims to strengthen Natco’s global footprint in advanced therapeutics. Financial details were not disclosed. 📊 *STOCKS:* $NATCOPHARM | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Investment

Natco Pharma acquires additional 13.25% stake in Adcock Ingram

*Natco Pharma acquires additional 13.25% stake in Adcock Ingram* — Natco Pharma has increased its holding in South Africa-based Adcock Ingram Holdings by acquiring an additional **13.25% stake**. This move strengthens its strategic footprint in the African pharmaceutical market. The acquisition enhances Natco’s control and potential revenue share in the joint venture. 📊 *STOCKS:* NATCOPHARM | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Acquisition

Natco Pharma rights issue period closes

*Natco Pharma rights issue period closes.* The subscription window for the rights issue has ended, with no further participation possible. Investors who applied will await confirmation and allotment details. The outcome will be announced by the company shortly. 📊 *STOCKS:* $NATCOPHARM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #RightsIssue

Natco Pharma and KEI Industries in focus ahead of results

*Natco Pharma and KEI Industries in focus ahead of results*. Traders are watching both stocks ahead of their quarterly earnings release. Key metrics like **revenue growth** and **profit margins** could drive F&O volatility. Options activity has increased with **open interest** rising in near-term contracts. 📊 *STOCKS:* $NATCOPHARM $KEI | 🏢 *SECTOR:* Pharma, Industrials | #MEDIUMIMPACT #Earnings

Natco Pharma to hold shareholder meeting on Sept 30, 2026

*Natco Pharma to hold shareholder meeting on Sept 30, 2026.* This is a routine corporate event as per regulatory requirements. No financial or strategic announcements were disclosed. Such meetings typically cover statutory matters and do not impact operations. 📊 *STOCKS:* $NATCOPHARM | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ShareholdersMeeting